Article ID Journal Published Year Pages File Type
9101387 Seminars in Arthritis and Rheumatism 2005 12 Pages PDF
Abstract
In the era of biologics and combination therapy, identifying remission or at least very low disease activity as the ultimate goal in RA therapy should become the new standard for the outcome of all RA trials. The criteria established by the FDA, the ACR, and the EULAR represent an important step toward achieving this goal.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, ,